<<
>>

: . . .. - , .. , .. . .: , 2000. .. . ., 1952. .. : . .... . . . ., 2001.

.., .., .., .. .

- -. . 1992; 10: 50-52. .., .. . , . 2003; 48(12): 29-32. .. . 2005; 4/5: 52-53. . . .. , .. , .. . . 2. ., 1961: 1061-1071. .. - - : . . ... - . . ., 1992. .. : . .: , 2006. Aoki N., Tateda ., Kikuchi Y. etal. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug- resistant Pseudomonas aeruginosa. J. Anti- microb. Chemother. 2009; 63: 534-542. Alothman G.A., Ho B., Alsaadi M.M. ef al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005; 127: 522-529. Anisimov A.P., Dentovskaya S.V., Titareva G.M. et al. Intraspecies and temperature- dependent variations in susceptibility of Yersinia pestis to the bactericidal action of serum and to polymyxin B. Infect. Immun. 2005; 73(11): 7324-7331. Benedict R.G., Langlykke A.F. Antibiotic activity of Bacillus polymyxa. J. Bacteri- ol. 1947; 54: 24-25. Champlin F.R., Gillelamd H.E., Conrad R.S.

Conversion of phospholipids to free fatty acids in response to acquisition of polymyxin resistance in Pseudomonas aeruginosa. An- timicrob. Agents Chemother. 1983; 24: 5-9. Conrad R.S., Galanos C. Fatty acid alterations and polymyxin binding by lipopoly- saccharides from Pseudomonas aeruginosa adapted to polymyxin resistance. Antimi- crob. Agents Chemother. 1989; 33: 1724-1728. Conway S.P., Etherington C., Munday J. et al. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann. Pharmacother. 2000; 34: 1238-1242. Conway S.P., Pond M.N., Watson A. et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987993. C.E., Harris on L.H. Intravenous sodium colistimethate therapy of urinary tract infections: pharmacological and bacteriological studies. Antimicrob. Agents Chemother. 1970; 1970: 296-302. Cox A.D., Wilkinson S.G. Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol. Microbiol. 1991; 5: 641-646. Cunningham S., Prasad A., Collyer L. et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch. Dis. Child 2001; 84: 432-433. Doroszkiewicz W., Cisowska A., Jankowski S. et al. The susceptibility of gram-negative rods and their adaptive forms resistant to colistine to the bactericidal action of sera.

Acta Microbiol. Pol. 1998; 47: 275-281. Gilleland H.E., Farley L.B. Adaptive resistance to polymyxin in Pseudomonas aeruginosa due to an outer membrane impermeability mechanism. Can. J. Microbiol. 1982; 28: 830-840. Gilleland H.E., Lyle R.D. Chemical alterations in cell envelopes of polymyxin-resistant Pseudomonas aeruginosa isolates. J. Bacteriol. 1979; 138: 839-845. Goodwin N.J., Friedman E.A. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann. Intern. Med. 1968; 68: 984994. Groisman E.A., Kayser J., Soncini F.C. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J. Bacteriol. 1997; 179: 7040-7045. Gutsmann T., Hagge S.O., David A. et al.

Lipid-mediated resistance of Gram-negative bacteria against various pore-forming antimicrobial peptides. J. Endotoxin Res. 2005; 11: 167-173. Hancock R.E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 2001; 1: 156-164. Hase S., Rietschel E.T. The chemical structure of the lipid A component of lipopolysac- charides from Chromobacterium violaceum NCTC 9694. Eur. J. Biochem. 1977; 75: 23-34. Jiaravuthisan M.M., DeKoven J.G. Contact dermatitis to polymyxin B. Contact. Dermatitis 2008; 59: 314-316. Kanesaka S., Sasaki J., Kuzume ei al. Effect of direct hemoperfusion using polymyxin immobilized fiber on inflammatory mediators in patients with severe sepsis and septic shock. Int. J. Artif. Organs 2008; 31: 891-897. Koyama Y., Kurosasa A., Tsuchiya A., Taka- kufa K. A new antibiotic colistin produced by spore-forming soil bacteria. J. Antibiot. 1950; 3: 457-458. Kucers A., Crowe S., Grayson M.L., Hoy J. (eds.) The use of antibiotics, 5th edn. Oxford: Butterworth-Heinemann, 1997: 667-675. Landman D., Georgescu C., Marlin D.A., Quale J. Polymyxins Revisited. Clin. Microbiol. Rev. 2008; 21: 449-465. Ledson M.J., Gallagher M.J., Cowperth- waite C. et al. Four years experience of intravenous colomycin in an adult cystic fibrosis unit. Eur. Respir. J. 1998; 12: 592-594. Leiva M., Moreno E., Ruiz-Bravo A., Jimenez-Valera M. Immunomodulation by non-absorbable antibiotics given by the intragastric route. Int. J. Antimicrob. Agents 2005; 25: 252-255. Levin A.S., Barone A.A., Penco J. et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 1999; 28: 10081011. Li J., Nation R.L., Turnidge J.D. et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect. Dis. 2006; 6: 589-601. MacKay D.N., Kaye D. Serum concentrations of colistin in patients with normal and impaired renal function. N. Engl. J. Med. 1964; 270: 394-397. Mares J., Kumaran S., Gobbo M., Zerbe O.

Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy. J. Biol. Chem. 2009; 284: 11498-11506. Markou N., Apostolakos H., Koumoudiou C. et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit. Care 2003; 7: 78-83. Matsushima S., Shichi H. Possible mechanism of immunosuppression by gramicidin S of S antigen-induced experimental autoimmune uveoretinitis. J. Ocul. Pharmacol. 1989; 5: 261-269. Matsushima S., Yoshitoshi T., Mahalak S.M., Shichi H. Immunosuppressive effect of gramicidin S on experimental ocular neuritis and allergic encephalomyelitis. Jpn. J. Ophthalmol. 1990; 34(3): 306-313. Matsushima S., Yoshitoshi T., Shichi H. Immunosuppression by gramicidin S of experimental autoimmune uveoretinitis, pinealitis and autoimmune encephalomyelitis. J. Ocul. Pharmacol. 1990; 6: 219-226. 4/ I., Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell Mol. Life Sci. 2009; 66: 3821-3826. Nishibori M., Takahashi H.K., Katayama H.

et al. Specific Removal of Monocytes from Peripheral Blood of Septic Patients by Polymyxin -immobilized Filter Column. Acta Med. Okayama 2009; 63: 65-69. Pankey G.A., Ashcraft D.S. The detection of synergy between meropenem and polymyxin against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn. Microbiol. Infect. Dis. 2009; 63: 228-232. Reed M.D., Stern R.C., O'Riordan M.A., Blumer J.L. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 2001; 41: 645-654. Rif kind D. Prevention by polymyxin of endotoxin lethality in mice. J. Bacteriol. 1967; 93: 1463-1464.

Shand G.H., Anwar H., Brown M.R.W. Outer membrane proteins of polymyxin resistant Pseudomonas aeruginosa: effect of magnesium depletion. J. Antimicrob. Chemother. 1988; 22: 811-821. Shimomura H., Mafsuura M., Saito S. et at.

Unusual interaction of a lipopolysaccharide isolated from Burkholderia cepacia with polymyxin B. Infect. Immun. 2003; 71: 52255230. Sidorczyk Z., Zahringer U., Rietschel E.T.

Chemical structure of the lipid A component of the lipopolysaccharide from a Proteus mi- rabilis Re-mutant. Eur. J. Microbiol. 1983; 13: 715-722. Sfansly P.G., Shepherd R.G., White H.J.

Polymyxin: a new chemotherapeutic agent. Johns Hopk. Hosp. Bull. 1947; 81: 43-54. Tamura 4., Nagano Y. Modulation by polymyxin of the effects of interferon on human myelogenous leukemia cells. Microbiol. Immunol. 1994; 38: 407-411. Warren H.S., Kania S.A., Siber G.R. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother. 1985; 28: 107-112. Wolinsky E., Hines J.D. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N. Engl. J. Med. 1972; 266: 759-762. Yeh T.M., ChaoS.C., Chang H.C. Lipopolysaccharide binding and antibacterial activities of a synthetic peptide representing amino acids 90-101 of bactericidal/permeability-increas- ing protein. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1994; 27:120-132.

<< | >>
: .. , .. , .. . 2012. 2012

:

- - - -
- - - - - - - - - - - - - -